Dr. Siva Iyer

Education & Board Certification

Fellowship – Ophthalmology
Louisiana State University
2013

Residency – Ophthalmology
University of Tennessee
2011

Internship – Surgery
Harvard University
2007

Medical Degree
University of Florida
2006

Board Certification

• Opthalmology – American Board of Ophthalmology

Clinical Interests

Publications

Idiopathic Orbital Inflammation in the Postpartum Period Associated With Preeclampsia.

Journal of neuro-ophthalmology: the official journal of the North American Neuro-Ophthalmology Society
2022

The Vitreous Ecosystem in Diabetic Retinopathy: Insight into the Patho-Mechanisms of Disease.
International journal of molecular sciences
2021

Peripheral Retinal Neovascularization in a Patient with Sarcoidosis and Cocaine-Associated Autoimmunity.
Case reports in ophthalmological medicine
2021

Exacerbation of pigment epithelial detachment following aflibercept: A case of bevacizumab rescue.
American journal of ophthalmology case reports
2021

Effect of pattern scanning laser on macular thickness in diabetic retinopathy.
Therapeutic advances in ophthalmology
2021

Bilateral anterior segment dysgenesis and persistent fetal vasculature associated with terminal 10q26 deletion.
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2021

Utility of wound cultures in the management of open globe injuries: a 5-year retrospective review.
Journal of ophthalmic inflammation and infection
2020

Treatment of Recurrent Primary Cutaneous Mucinous Carcinoma of the Eyelid with Modified Wide Local Excision.
Case reports in ophthalmological medicine
2020

Endogenous Endophthalmitis: yield of the diagnostic evaluation.
BMC ophthalmology
2020

Eicosanoid Profiles in the Vitreous Humor of Patients with Proliferative Diabetic Retinopathy.
International journal of molecular sciences
2020

Bilateral pseudohypopyon causing white eyes in a patient with lymphoma.
Lancet (London, England)
2020

Surgical management of diabetic tractional retinal detachments.
Survey of ophthalmology
2019

Exercise band-induced lens dislocations: A case series.
American journal of ophthalmology case reports
2019

Dosimetric dependence of ocular structures on eye size and shape for external radiation fields of electrons, photons, and neutrons.
Journal of radiological protection : official journal of the Society for Radiological Protection
2019

Vision loss secondary to orbital extension of rhabdomyosarcoma in an adult.
Clinical & experimental ophthalmology
2018

Ophthalmic artery occlusion after chiropractic neck manipulation.
Acta ophthalmologica
2018

Multiloculated Ciliary Body Cysts and Lenticular Coloboma: A Rare Phenotypic Variation Associated With Persistent Fetal Vasculature.
Journal of pediatric ophthalmology and strabismus
2018

A scalable and deformable stylized model of the adult human eye for radiation dose assessment.
Physics in medicine and biology
2018

A Young Patient With Floaters.
JAMA ophthalmology
2018

Intralenticular Ozurdex® – One Year Later.
Case reports in ophthalmology
2017

Clinical Research Protocols

HAWK – NCT02307682 – Efficacy and Safety of RTH258 Versus Aflibercept – The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye. – Alcon.

PROXIMA A – NCT02479386 – Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration – This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study is also intended to generate new information on the relationship between genetics and GA progression. – Hoffmann-La Roche.

CEDAR – NCT02462928 – Safety and Efficacy Study of Abicipar Pegol in Patients With
Neovascular Age-related Macular Degeneration – This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration. – Allergan.

ORBIT – NCT02079883 – Ocriplasmin Research to Better Inform Treatment – Multicenter, prospective, observational, Phase 4 study assessing clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes. – Thrombogenics.

SHORE – NCT01277302 – A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion – This was a Phase IV multicenter, randomized, open-label study, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). – Genentech.

FOVEA (FOV2304) – NCT01319487 – Safety and Efficacy Study of Topical Administration
of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy – The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of treatment. – Fovea Pharmaceuticals SA.

Novartis HMT – NCT01542866 – A 16-Week Evaluation of the Novartis Health Management Tool (HMT) in Age-Related Macular Degeneration – This is a prospective pilot study to evaluate the usability and applicability of a self-monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age-Related Macular Degeneration (AMD) to detect a potential change in disease status. – Novartis Pharmaceuticals.

DODO (FVF4155s) – NCT00533520 – Evaluation of Dosing Interval of Higher Doses of
Ranibizumab – Phase 4 study to test the safety, tolerability and effectiveness of a higher doses (1.0 mg and 2.0 mg) of ranibizumab versus the standard dose (0.5 mg), in adults with age-related macular degeneration who have never been treated with ranibizumab. – Genentech.

VISTA – NCT01363440 – Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema – The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection on the best corrected visual acuity (BCVA) in patients with diabetic macular edema (DME) with central involvement.- Regeneron Pharmaceuticals.

Foresee Home Device Study (PT US 001) – NCT01334294 – Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age-Related Macular Degeneration. – The purpose of the current study is to evaluate if, in post-treatment patients, PHP parameters as measured with the ForeseeHome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography (OCT). – Notal Vision Ltd.

MAHALO – NCT01229215 – A Study of Safety, Tolerability, and Evidence of Activity of
FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy – Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy. – Genentech.

Research Experience

1998-2002 Baylor College of Medicine – Houston, TX
Department of Immunology and the Center for Cell and Gene Therapy
Advisor: Michael A. Barry, Ph.D.
M.D./Ph.D. Candidate – investigated the targeting of retroviral and adenoviral vectors to selected cell types by modifying the viral envelopes and capsid proteins of gene therapy viral vectors

1994-1995 University of Tennessee School of Veterinary Medicine – Knoxville, TN
Department of Orthopedic Surgery
Advisor: Jack Wasserman, Ph.D.
Biomedical Engineering Honors Thesis – tested structural integrity and compared biomechanical properties of a novel PMMA trans-hock external fixation device versus a traditional KE stainless-steel fixation device

1992-93 Oak Ridge National Laboratory – Oak Ridge, TN
Chemical Engineering Division Consultant – completed uranium contamination resorption project and trained post-doctoral engineer in newly established protocols

1992 Oak Ridge National Laboratory – Oak Ridge, TN
Chemical Engineering Division Research Intern – assisted in the design and testing of a biologically based uranium absorption system for the purification of uranium-contaminated water

1991 Oak Ridge National Laboratory – Oak Ridge, TN
Energy Sciences Division Research Intern – investigated enhancing the efficiency of heat pump technology through innovative design and use of computer models to test the efficiency of prototype heat pumps

Oral Presentations

Nov 2015 Oral Platform Presentation – Vision Loss Consequent to Intravitreal Stem Cell Injection
Albini TA, Kuriyan AE, Townsend JH, Rodriguez M, Pandya HK, Leonard RE, Parrott MB, Rosenfeld PJ, Flynn HW
2015 Annual Meeting – American Academy of Ophthalmology – Las Vegas, NV

Nov 2008 Poster – Nosocomial Acute-onset postoperative endophthalmitis at a university teaching hospital Wykoff CC, Flynn HW, Miller D, Parrott MB, Murray TG, Smiddy WE, Davis JL
2008 Annual Meeting – American Academy of Ophthalmology

Nov 2007 Poster – Intravitreal bevacizumab use for progressive ROP and Best disease related choroidal neovascular membranes
Parrott MB, Murray, TG, and Berrocal AM
2007 Annual Meeting – American Academy of Ophthalmology

June 2007 Oral Platform Presentation – Nosocomial acute-onset postoperative endophthalmitis survey: An 11-year review of incidence, causative organisms, and outcomes
Parrott MB, Wykoff CC, and Flynn HW
43rd Annual Bascom Palmer Eye Institute Resident’s Day – Miami, FL

May 2007 Poster – Nosocomial acute-onset postoperative endophthalmitis survey: An 11-year review of incidence, causative organisms, and outcomes
Parrott MB, Wykoff CC, Miller D, Newton J, and Flynn HW
ARVO 2007 Annual Meeting – Fort Lauderdale, FL

June 2003 Oral Platform Presentation – Metabolically Biotinylated Viruses for Vector Targeting and Purification Campos SK, Parrott MB, Adams KE, and Barry MA
Sixth Annual Meeting of the American Society of Gene Therapy – Washington, DC

March 2003 Poster – Metabolically biotinylated gene therapy vectors for vector targeting and purification
Campos SK, Parrott MB, Adams KE, Blum JS, Mok H, Muzykantov V, and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

March 2003 Poster – Selection and application of CLL-targeting peptides using peptide-presenting phage libraries
Takahashi S, Mok H, Parrott MB, Marini FC, Andreeff M, Brenner MK, and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

Jan. 2003 Poster – Apoptosis, mitotic rate, and age correlations in the regression of periorbital hemangiomas
Parrott MB, Font RL, and Chevez-Barrios P
Eighty-Second Annual Texas Society of Pathologists Meeting – Houston, TX

June 2002 Oral Platform Presentation – Metabolically biotinylated adenoviral vectors for targeted gene therapy
Parrott MB and Barry MA
Fifth Annual Meeting of the American Society of Gene Therapy – Boston, MA

May 2002 Oral Platform Presentation – Use of in vivo biotinylated adenoviral vectors for targeted gene therapy
Parrott MB and Barry MA
Forty-Third Annual National Student Research Forum – Galveston, TX

Dec. 2001 Poster – Selection of leukemia-targeting peptides using peptide presenting phage libraries
Takahashi S, Barry ME, Parrott MB, Brenner MK, and Barry MA
Forty-Third American Society of Hematology Annual Meeting – Orlando, FL

June 2001 Poster – Metabolically biotinylated gene therapy vectors
Parrott MB and Barry MA
Fourth Annual Meeting of the American Society of Gene Therapy – Seattle, WA

March 2001 Oral Platform Presentation – Metabolically biotinylated adenoviral and retroviral vectors
Parrott MB and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

June 2000 Poster – Metabolic biotinylation of recombinant proteins for viral gene therapy vector targeting
Parrott MB and Barry MA
Third Annual Meeting of the American Society of Gene Therapy – Denver, CO

March 1999 Poster – Selecting lung targeting peptides in vivo
Parrott MB and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

Teaching Experience

2009-2010 –   Chief Resident, BPEI
2006-2009 –  Teaching Assistant for Neuro-Ophthalmology Course, BPEI
1997-2004 –   Teaching Assistant and Graduate Lecturer, Department of Immunology, BCM
2003 –             Conference Leader, Department of Pathology, BCM
1996-1999 –   Conference Leader and Graduate Lecturer, Physiology, BCM
1996-2000-   Student Affairs Tutor, Biochemistry and Physiology, BCM
1995 –              Engineering Specialty Course – Tennessee Governor’s School for the Sciences, UTK

Grants and Fellowships

2003-2004 –  American Medical Association Foundation Research Seed Grant
1999-2002 –   National Research Service Award from National Institutes of Health
1995-2004 –   National Institutes of Health – Medical Scientist Training Program Grant

Professional Organizations

American Society of Retina Specialists
American Academy of Ophthalmology
Association for Research in Vision and Ophthalmology
Alpha Omega Alpha Honor Medical Society
American Society for Gene Therapy
Tau Beta Pi (Engineering)
American Medical Student Association
Texas Medical Student Association
Texas Society of Pathologists
Baylor Pediatrics Student Association – Research Coordinator